MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study
Christiane Copie-Bergman, Peggy Cuillière-Dartigues, Maryse Baia, Josette Briere, Richard Delarue, Danielle Canioni, Gilles Salles, Marie Parrens, Karim Belhadj, Bettina Fabiani, Christian Recher, Tony Petrella, Nicolas Ketterer, Frederic Peyrade, Corinne Haioun, Inga Nagel, Reiner Siebert, Fabrice Jardin, Karen Leroy, Jean-Philippe Jais, Herve Tilly, Thierry Jo Molina, Philippe Gaulard, Christiane Copie-Bergman, Peggy Cuillière-Dartigues, Maryse Baia, Josette Briere, Richard Delarue, Danielle Canioni, Gilles Salles, Marie Parrens, Karim Belhadj, Bettina Fabiani, Christian Recher, Tony Petrella, Nicolas Ketterer, Frederic Peyrade, Corinne Haioun, Inga Nagel, Reiner Siebert, Fabrice Jardin, Karen Leroy, Jean-Philippe Jais, Herve Tilly, Thierry Jo Molina, Philippe Gaulard
Abstract
Diffuse large B-cell lymphoma (DLBCL) with MYC rearrangement (MYC-R) carries an unfavorable outcome. We explored the prognostic value of the MYC translocation partner gene in a series of MYC-R de novo DLBCL patients enrolled in first-line prospective clinical trials (Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association) and treated with rituximab-anthracycline-based chemotherapy. A total of 774 DLBCL cases characterized for cell of origin by the Hans classifier were analyzed using fluorescence in situ hybridization with BCL2, BCL6, MYC, immunoglobulin (IG)K, and IGL break-apart and IGH/MYC, IGK/MYC, and IGL/MYC fusion probes. MYC-R was observed in 51/574 (8.9%) evaluable DLBCL cases. MYC-R cases were predominantly of the germinal center B-cell-like subtype 37/51 (74%) with no distinctive morphologic and phenotypic features. Nineteen cases were MYC single-hit and 32 cases were MYC double-hit (MYC plus BCL2 and/or BCL6) DLBCL. MYC translocation partner was an IG gene in 24 cases (MYC-IG) and a non-IG gene (MYC-non-IG) in 26 of 50 evaluable cases. Noteworthy, MYC-IG patients had shorter overall survival (OS) (P = .0002) compared with MYC-negative patients, whereas no survival difference was observed between MYC-non-IG and MYC-negative patients. In multivariate analyses, MYC-IG predicted poor progression-free survival (P = .0051) and OS (P = .0006) independently from the International Prognostic Index and the Hans classifier. In conclusion, we show in this prospective randomized trial that the adverse prognostic impact of MYC-R is correlated to the MYC-IG translocation partner gene in DLBCL patients treated with immunochemotherapy. These results may have an important impact on the clinical management of DLBCL patients with MYC-R who should be routinely characterized according to MYC partner gene. These trials are individually registered at www.clinicaltrials.gov as #NCT00144807, #NCT01087424, #NCT00169143, #NCT00144755, #NCT00140660, #NCT00140595, and #NCT00135499.
© 2015 by The American Society of Hematology.
Source: PubMed